Clinical Trials

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05372640 2026-04-13

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

45 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05687110 2026-04-13

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

43 enrolled

Neoplasm Metastasis

NCT05687136 2026-04-13

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

66 enrolled

Neoplasm Metastasis

NCT05691517 2026-04-13

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

35 enrolled

Neoplasm Metastasis

NCT05803382 2026-04-13

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

30 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT06223542 2026-04-13

Studying TAK-243 in Patients With Advanced Cancer

95 enrolled

Neoplasm Metastasis

NCT06364410 2026-04-13

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

48 enrolled

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT06606990 2026-04-13

Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers

40 enrolled

Neoplasm Metastasis

NCT07137416 2026-04-13

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

36 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

18 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT05098210 2026-03-12

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

25 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT04294628 2026-02-27

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

62 enrolled

GastrointestinalSarcomaThoracic

Neoplasm Metastasis

NCT02408861 2026-01-21

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Terminated

79 enrolled 24 charts

Anus Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Sarcoma, Kaposi, HIV Infections

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

BreastGastrointestinalGynecologic

18 enrolled

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06043713 2025-12-19

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

24 enrolled

Neoplasm Metastasis

NCT04329494 2025-12-10

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

GastrointestinalGynecologic

49 enrolled

Appendiceal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Phase 1 Terminated

36 enrolled 7 charts

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03842228 2025-10-14

COD

39 enrolled 15 charts

Neoplasm Metastasis

NCT06942104 2025-07-18

Imaging of Solid Tumors Using 18F-TRX

56 enrolled

CNSGenitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Glioma, Neoplasm Metastasis, Prostatic Neoplasms

NCT04514497 2025-03-06

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

EndocrineGastrointestinalThoracic

28 enrolled

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05653661 2025-01-07

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Withdrawn